Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($) $ in Millions		12 Months Ended
	Apr. 01, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues		$ 16,071.7	$ 8,497.1	$ 6,557.6
Sanofi Collaboration Agreement, Antibody
Disaggregation of Revenue [Line Items]
Percentage of quarterly profits require to be paid for reimbursement of development costs		10.00%
Contingent reimbursement obligation		$ 3,152.0
Starting share of profits outside the United States, based on sales, for collaborating party		65.00%
Starting share of profits outside the United States, based on sales, for company		35.00%
Ending share of profits outside the United States, based on sales, for collaborating party		55.00%
Ending share of profits outside the United States, based on sales, for company		45.00%
Share of losses outside the United States, for collaborating party		55.00%
Share of losses outside the United States, for company		45.00%
Revenue, remaining performance obligation, variable consideration amount		$ 150.0
Sanofi Collaboration Agreement, Antibody | First Milestone
Disaggregation of Revenue [Line Items]
Revenues			50.0
Levels of twelve month sales at which sales milestone payments would be received			$ 1,000.0
Period for achieving sales target for milestone payment, rolling basis			12 months
Sanofi Collaboration Agreement, Antibody | Second Milestone
Disaggregation of Revenue [Line Items]
Levels of twelve month sales at which sales milestone payments would be received		1,500.0
Sanofi Collaboration Agreement, Antibody | Third Milestone
Disaggregation of Revenue [Line Items]
Levels of twelve month sales at which sales milestone payments would be received		$ 2,000.0
Period for achieving sales target for milestone payment, rolling basis		12 months
Revenue, remaining performance obligation, variable consideration amount		$ 50.0
Sanofi Collaboration Agreement, Antibody | Minimum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party		80.00%
Percentage of repayment of development balance out of profits		30.00%
Sanofi Collaboration Agreement, Antibody | Maximum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party		100.00%
Percentage of repayment of development balance out of profits		50.00%
Praluent Agreement
Disaggregation of Revenue [Line Items]
Royalty percentage to be received on net product sales outside of the United States	5.00%
Percentage of damages company is responsible for	50.00%
Praluent Agreement | Sanofi
Disaggregation of Revenue [Line Items]
Percentage of royalty payment that can be used to offset litigation proceedings	50.00%